welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
The committee will discuss biologics license application (BLA) 761143, teprotumumab solution for intravenous use, submitted by Horizon Pharma Ireland, Ltd., proposed for the treatment of active thyroid eye disease.
The public participation information has been changed for the December 13, 2019 Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee. The deadline for making formal oral presentation requests has been changed from Tuesday, November 26, 2019 to Monday, December 2, 2019. The deadline for submitting electronic or written comments to be provided to the committee has been changed from Wednesday, December 4, 2019 to Monday, December 9, 2019.
Date & Time:
December 13, 2019
8:00 AM to 4:00 PM
FDA White Oak Campus
10903 New Hampshire Avenue
Building 31 Conference Center
The Great Room (Rm. 1503)
Silver Spring, Maryland, United States
This event has ended.
Evaluation of Quality of Life in Patients With Graves´ Ophthalmopathy, Before and After Orbital DecompressionGraves' ophthalmopathy (GO) is a potenti...
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presen...Horizon Therapeutics plc today announced...
Graves’ and Thyroid Eye Disease Support Group MeetingThis event is hosted by Graves' Dise...
Rituximab Offers No Benefit Over Placebo to Patients With Active or Moderate-to-Severe Graves’ OrbitopathyPrevention of Graves' orbitopathy (GO) r...
Type 2 Diabetic Patients With Graves’ Disease Have More Frequent and Severe Graves’ OrbitopathyBackground and Aims: Due to the worldwi...
Meta-Analysis of Methylprednisolone Pulse Therapy for Graves’ OphthalmopathyA meta-analysis was performed to evaluat...
The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves’ Ophthalmopathy PatientsPurpose: The purpose of this study is t...